Category Archives for "News"

ABATTIS STRENGTHENS MANAGEMENT TEAM AND PROVIDES COMPANY UPDATES

ABATTIS STRENGTHENS MANAGEMENT TEAM AND PROVIDES COMPANY UPDATES September 11, 2018    |    Abattis Bioceuticals Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to provide the following corporate updates. The Company is pleased to announce the appointment of Nicole Breitinger as the Company’s corporate secretary. Ms. Breitinger brings considerable experience to […]

Read More

ABATTIS PREPARES TO LAUNCH NEW PRODUCTS THROUGH VERGENCE NATURALS

ABATTIS PREPARES TO LAUNCH NEW PRODUCTS THROUGH VERGENCE NATURALS August 28, 2018    |    Abattis Bioceuticals Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that it plans to launch a new line of products designed to alleviate pain and inflammation through its wholly owned subsidiary, Vergence Naturals Ltd. (“Vergence”). […]

Read More

ABATTIS COMPLETES SALE OF NORTHERN VINE INTEREST

ABATTIS COMPLETES SALE OF NORTHERN VINE INTEREST August 14, 2018    |    Abattis Bioceuticals Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that it has completed the sale (the “Sale”) of its 35% interest in Northern Vine Canada Inc. (“Northern Vine”) to Emerald Health Therapeutics, Inc. (TSXV:EMH / OTCQX:EMHTF) (“Emerald”) […]

Read More

ABATTIS ANNOUNCES SHARE BUY BACK PROGRAM

ABATTIS ANNOUNCES SHARE BUY BACK PROGRAM August 7, 2018    |    Abattis Bioceuticals Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that it intends to proceed with a normal course issuer bid to purchase up to 20,986,909 of its common shares, representing 5% of its current issued and outstanding […]

Read More
1 2 3 8